An observational study in IVF Outcomes, Prediction Models and Infertility Assisted Reproductive Technology, sponsored by BetaPlus Center for Reproductive Medicine. Recruiting at 2 sites in Croatia. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-10-07.
Sponsored by BetaPlus Center for Reproductive Medicine · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this observational study is to develop and validate a machine-learning model to predict pregnancy outcomes in women with a positive pregnancy test following assisted reproductive treatment (ART), with the primary analysis focusing on in vitro fertilization (IVF) and frozen embryo transfer (FET). The study will also include an exploratory analysis of pregnancies following intrauterine insemination (IUI). The main questions addressed by the study are:
Can early blood levels of beta-human chorionic gonadotropin (beta-hCG) predict the likelihood of live birth in an IVF or FET cycle? Can early beta-hCG levels help identify pregnancies at increased risk of biochemical pregnancy or early pregnancy loss?
Participants will have clinical and treatment information, including beta-hCG measurements and pregnancy outcomes, collected from medical records or during prospective follow-up. No changes to participants' medical treatment will be made as part of the study.
Infertility affects more than 15% of the global population, and ART are increasingly used to achieve pregnancy. The field continues to evolve rapidly with ongoing technological and clinical advances. Although these advances have improved ART, success rates continue to vary, contributing to significant psychological distress among patients due to uncertainty regarding outcomes.
The most intense stress typically occurs after the procedure, especially following a positive pregnancy test and before ultrasound confirmation. This period, which lasts at least 3-4 weeks, is characterized by considerable uncertainty, as neither patients nor healthcare providers have reliable tools to determine pregnancy viability, assess early development, or accurately predict pregnancy progression. An individualized assessment of the probability of live birth after a positive pregnancy test could provide clinically meaningful information during this period and potentially improve counseling and management of patient expectations.
Serum beta-hCG is one of the earliest measurable biomarkers following embryo implantation and has long been recognized as an important prognostic marker of early pregnancy outcome. Both the absolute concentration of beta-HCG and its subsequent rate of increase have been associated with pregnancy viability and live birth following embryo transfer.
Investigators plan to use a machine-learning system to collect and analyze retrospective clinical data. Beta-HCG values from this dataset were collected at very early stages of pregnancy (around aspiration days +14 and 16, and post-FET days 9 and 11).
Patients were advised to have blood drawn for beta-HCG measurement 14 days after oocyte aspiration or insemination, followed by a second measurement two days later. For FET, measurements were taken 9 days after blastocyst transfer (or the corresponding day for cleavage-stage embryos) and two days afterward. Due to scheduling constraints, such as weekends, actual measurements may have occurred one day earlier or later, or several days apart. The dataset included the exact dates of each blood draw, allowing precise calculation of the interval between measurements for analysis.
ART outcomes were primarily collected through direct patient reporting of events, including adverse pregnancy outcomes or live birth; for patients who did not report the outcomes, clinic staff conducted follow-up calls to ensure complete follow-up.
This study is an observational retrospective-prospective cohort study for development and validation of an AI (artificial intelligence) - based prognostic model predicting live birth after ART.
The retrospective phase will use existing clinical data from patients who underwent ART procedures at the BetaPlus Center between January 2017 and 31.12.2025.
The prospective phase will include consecutive patients undergoing ART after model development in both BetaPlus Center and Clinical University Hospital in Rijeka. These patients will be followed to assess pregnancy outcomes, enabling external validation of the model.
The study is observational in nature. No interventions, treatment modifications, or randomization will be performed as part of this research. Clinical management will follow standard operating procedures (SOP) independent of model predictions.
221 studies on the registry are indexed under Abortion, Spontaneous; 44 are open to participants now.
This study's planned enrollment of 2,200 is above the median of 201 across 98 observational studies indexed under Abortion, Spontaneous.
Browse Abortion, Spontaneous studies →This is the only study on the registry with BetaPlus Center for Reproductive Medicine as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Participants will be women undergoing ART at the BetaPlus Center and, during the prospective validation phase, at the Clinical University Hospital in Rijeka, Croatia. The study population will include patients undergoing IVF/ICSI, FET, or IUI.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with a positive serum beta-hCG measurement following ART, including IVF, FET, and IUI. Participants will be followed to assess pregnancy outcomes, including live birth, biochemical pregnancy, and early pregnancy loss.
Other: Machine-Learning Model for Prediction of Pregnancy Outcomes
A machine-learning prognostic model using early serum beta-hCG measurements and patient, embryo, and treatment characteristics to predict live birth and early adverse pregnancy outcomes following assisted reproductive treatment.
Live birth following ART
Delivery of a live infant at ≥24 weeks of gestation.
Time frame: From positive pregnancy test until delivery.
Biochemical pregnancy following ART
A pregnancy characterized by a positive serum beta-hCG test followed by bleeding or pregnancy loss without ultrasound confirmation of a clinical pregnancy.
Time frame: From the first positive serum beta-hCG measurement until biochemical pregnancy resolution.
Early Pregnancy Loss following ART
Pregnancy loss occurring before 12 weeks of gestation, excluding biochemical pregnancy, ectopic pregnancy, heterotopic pregnancy, and hydatidiform mole.
Time frame: From clinical pregnancy confirmation until 12 weeks of gestation.
Plan to share: Yes — De-identified individual participant data underlying the results of this study will be made available upon reasonable request. The shared dataset will include the clinical and treatment variables necessary to reproduce or further investigate the study findings, including relevant beta-hCG measurements, timing of measurements, ART treatment characteristics, and pregnancy outcomes. Data will not include names, contact information, medical record numbers, or other directly identifying information.
Supporting information: Study protocol, Statistical analysis plan
Time frame: After publication and for 5 years thereafter
Access criteria: Data will be available to qualified researchers, subject to applicable ethical, legal, and institutional requirements
Started Jan 2026 (actual). Primary completion is estimated for Dec 2026, 11 months after the start.
Of 43 observational studies under Abortion, Spontaneous, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 91. This study's planned 11 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.